Hormone replacement therapy marketing - HRT for menopause and perimenopause, TRT for men, bioidentical hormones, pellet therapy, compounded combinations - combines several regulatory layers that practices routinely collapse together. FDA-approved hormone products have prescription-drug advertising rules. Compounded hormones have the same compounded-drug equivalency issues as GLP-1s. Anti-aging and longevity claims trigger FTC enforcement on top of that. This post walks through the compliance framework for each.
The regulatory categories
Hormone therapies span several distinct regulatory categories:
- FDA-approved bioidentical hormones. Products like estradiol, estriol, progesterone, and testosterone that have FDA-approved forms available. Marketing these by brand name falls under prescription-drug advertising rules.
- Compounded bioidentical hormones. Prepared by licensed compounding pharmacies, often in combinations not commercially available. Subject to compounding-pharmacy rules plus marketing-equivalency issues similar to compounded GLP-1s.
- Hormone pellet therapy. Typically compounded formulations in subcutaneous pellet form. Marketing raises both compounded-drug and off-label-delivery-mechanism issues.
- Branded DHEA, pregnenolone, and adjacent products. Some are dietary supplements under DSHEA; some are compounded products; each has its own rules.
The specific problem patterns
Pattern 1: “Safer than synthetic hormones”
“Bioidentical hormones are safer than synthetic hormones - the body recognizes them naturally.”
“Our hormone replacement protocols use [specific products]. All hormone therapies carry risks and benefits that we discuss at consultation based on your personal and family medical history.”
Why: 'Safer than synthetic' is a comparative safety claim without adequate head-to-head substantiation. The FTC has specifically pursued this claim pattern in compounding-pharmacy and hormone-clinic contexts.
Pattern 2: Disease-prevention claims
“HRT prevents osteoporosis, heart disease, and Alzheimer's.”
“HRT is prescribed based on individual clinical indication, including for some patients with increased osteoporosis risk. Potential benefits and risks are reviewed at consultation.”
Why: Disease-prevention claims are FDA drug-claim territory. Menopausal hormone therapy has specific approved indications; extending those into general disease-prevention marketing is off-label promotion.
Pattern 3: Anti-aging reversal
“Reverse the aging process with our hormone optimization protocol.”
“Our hormone replacement protocols aim to address specific symptoms and lab-confirmed deficiencies when appropriate. We do not make claims about reversing aging generally.”
Why: Anti-aging reversal claims are an active FTC enforcement priority. The compliant framing focuses on symptom and deficiency management rather than aging reversal.
Pattern 4: Performance and body composition claims
“TRT - build muscle, lose fat, regain your edge.”
“Testosterone replacement therapy is prescribed for men with clinically diagnosed low testosterone. Some patients report improvements in energy, mood, and body composition; individual outcomes vary based on many factors.”
Why: Performance-optimization marketing of TRT has been specifically targeted by FDA warning letters and FTC actions. Clinical-indication framing (symptoms, lab values) is the compliant alternative.
Pattern 5: Pellet therapy equivalence
“Our pellet therapy gives you the same hormones as any other delivery - just more convenient.”
“Our pellet therapy is a compounded preparation delivered through subcutaneous insertion; pellets release hormones over approximately 3-5 months. Clinical candidacy is evaluated at consultation.”
Why: Pellets are a compounded delivery mechanism, not FDA-approved products. 'Same hormones' framing can mislead patients about the regulatory category.
Pattern 6: “Optimization” and lab-chasing framing
“Hormone optimization” marketing positions patients as optimization candidates based on lab values even when values are within normal ranges. The marketing implication - that you need treatment even without clinical symptoms of deficiency - has been a specific FDA and state medical board focus. Compliant framing treats clinical symptoms plus confirmed deficiency as the indication.
Compliant hormone therapy marketing framework
Lead with symptom evaluation
“Our practice evaluates patients with symptoms potentially related to hormone changes - fatigue, sleep disruption, mood changes, low libido, body composition changes - with comprehensive medical history and appropriate laboratory testing.” Symptom-forward framing positions the service as clinical care.
Describe the evaluation process
“Treatment decisions are based on clinical symptoms, physical examination, and laboratory values interpreted in the context of your overall health. We offer FDA-approved hormone therapies and, when appropriate, compounded preparations.” Process-forward framing is both compliant and positions the practice as thorough.
Be specific about products and delivery
“We prescribe [specific products] in [specific delivery forms] based on individual patient needs.” Generic “we do HRT” marketing is less effective and less compliant than specific product-and-protocol descriptions.
Acknowledge risks openly
“All hormone therapies carry risks including [list common risks]. We review specific risks and benefits with each patient based on personal and family medical history, including any history of hormone-sensitive cancers.” This is compliant fair-balance framing and appropriate clinical communication.
State-specific telehealth considerations
Telehealth hormone practices face additional state-by-state rules on prescribing across state lines, supervision requirements, and pellet-insertion scope-of- practice issues. State medical boards in California, Texas, and Florida have been particularly active on telehealth hormone marketing.
Frequently asked questions
Is compounded hormone marketing the same as compounded GLP-1?
The regulatory framework is similar. Compounded hormones are not FDA-approved; marketing them as equivalent to FDA-approved alternatives is a substantiation and misbranding issue. The specific claim patterns under enforcement overlap with compounded-GLP-1 enforcement.
Can I say “bioidentical”?
The term itself is usable but the framing matters. Bioidentical hormones include both FDA-approved products (estradiol, progesterone) and compounded preparations. Marketing the compounded versions specifically as superior to FDA-approved alternatives is a specific enforcement pattern.
What about DHEA, pregnenolone, and related products?
DHEA is sold as a dietary supplement and prescribed in some forms. Pregnenolone is primarily sold as a supplement. Marketing them with disease claims or as prescription-drug alternatives creates the same structure-function vs disease-claim issues as any supplement marketing.
Do I need to disclose financial relationships with compounding pharmacies?
State laws vary on physician-compounding pharmacy relationships. Some states require specific disclosures; some have broader anti-kickback rules that affect the relationship. Consult state-specific counsel on your specific arrangement.
What about “low T” marketing specifically?
“Low T” as marketing shorthand for low testosterone has its own enforcement history - the FDA issued specific warnings about over-diagnosis and inappropriate prescribing marketing. Marketing should focus on clinical symptom evaluation rather than implying broad low-testosterone epidemic framing.
How does HRT marketing intersect with weight-loss marketing?
Practices combining hormone and weight-loss services layer both regulatory frameworks. Weight-loss testimonials tied to hormone therapy carry both Jenny Craig precedent rules and FDA hormone-advertising rules. Keep the marketing of each service independently compliant and be cautious about cross-service outcome claims.